Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2-positive (HER2+) esophageal, gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 (DG-03) Meeting Abstract
| Authors: | Janjigian, Y. Y.; van Laarhoven, H. W. M.; Rha, S. Y.; Kozlov, V.; Oh, D. Y.; Gravina, A.; Rapatoni, L.; Shoji, H.; Hofheinz, R. D.; Chen, L. T.; Ford, H. E. R.; Chenard-Poirier, M.; Raoufmoghaddam, S.; Lloyd, C.; Zhang, C.; Mateo, C.; Lee, J. |
| Abstract Title: | Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2-positive (HER2+) esophageal, gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 (DG-03) |
| Meeting Title: | ESMO Congress 2024 |
| Journal Title: | Annals of Oncology |
| Volume: | 35 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2024 Sep 13-17 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-09-01 |
| Start Page: | S878 |
| Language: | English |
| ACCESSION: | WOS:001326612902023 |
| DOI: | 10.1016/j.annonc.2024.08.1467 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1401O -- Source: Wos |
